Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
waveLINE-006 study of zilovertamab vedotin with or without nemtabrutinib in relapsed or refractory B-cell malignancies
2022-501374-19-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Feb 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 21
01
Overview
Phase 2, open-label trial of zilovertamab vedotin and nemtabrutinib in mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL) and 1 more (5 cohorts), sponsored by Merck & Co. Primary endpoints: Percentage of participants with at least 1 adverse event, Percentage of participants who discontinue study therapy due to adverse event and 4 more. Planned start Feb 2024; status: authorised.
02
Drugs
zilovertamab vedotinnemtabrutinib
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)follicular lymphoma (FL)Richter's syndrome (RS)
Beyond the preview
Go deeper on 2022-501374-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501374-19-00.